{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:41:18Z","timestamp":1794476478771,"version":"4.9.1"},"reference-count":655,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.<\/jats:p>","DOI":"10.1093\/cid\/ciw326","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T01:50:53Z","timestamp":1467337853000},"page":"e1-e60","source":"Crossref","is-referenced-by-count":2648,"title":["Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America"],"prefix":"10.1093","volume":"63","author":[{"given":"Thomas F.","family":"Patterson","sequence":"first","affiliation":[{"name":"\u00a0University of Texas Health Science Center at San Antonio and South Texas Veterans Health Care System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[{"name":"\u00a0University of California, Davis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Denning","sequence":"additional","affiliation":[{"name":"\u00a0National Aspergillosis Centre, University Hospital of South Manchester, University of Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Fishman","sequence":"additional","affiliation":[{"name":"\u00a0Massachusetts General Hospital and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hadley","sequence":"additional","affiliation":[{"name":"\u00a0Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[{"name":"\u00a0University of Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"\u00a0University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren A.","family":"Marr","sequence":"additional","affiliation":[{"name":"\u00a0Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki A.","family":"Morrison","sequence":"additional","affiliation":[{"name":"\u00a0Hennepin County Medical Center and University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"\u00a0University of Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahm H.","family":"Segal","sequence":"additional","affiliation":[{"name":"\u00a0University at Buffalo Jacobs School of Medicine and Biomedical Sciences, and Roswell Park Cancer Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Steinbach","sequence":"additional","affiliation":[{"name":"\u00a0Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Stevens","sequence":"additional","affiliation":[{"name":"\u00a0California Institute for Medical Research, San Jose"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"\u00a0New York\u2013Presbyterian Hospital\/Weill Cornell Medical Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"\u00a0University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne H.","family":"Young","sequence":"additional","affiliation":[{"name":"\u00a0University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Bennett","sequence":"additional","affiliation":[{"name":"\u00a0Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"2020110410412589300_CIW326C1","article-title":"Approach and implications to rating the quality of evidence and strength of recommendations using the GRADE methodology","author":"US GRADE Network"},{"key":"2020110410412589300_CIW326C2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2020110410412589300_CIW326C4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020110410412589300_CIW326C5","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1086\/652761","article-title":"Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation","volume":"50","author":"Panackal","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/clinids\/22.3.521","article-title":"Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine","volume":"22","author":"Oliver","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJMc1407928","article-title":"Adverse health effects of marijuana use","volume":"371","author":"Thompson","year":"2014","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinids\/22.6.1102","article-title":"Primary cutaneous aspergillosis in neonates: case report and review","volume":"22","author":"Papouli","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C9","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1128\/JCM.36.11.3115-3121.1998","article-title":"Cutaneous aspergillosis","volume":"36","author":"van Burik","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jhin.2011.06.012","article-title":"Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit","volume":"79","author":"Etienne","year":"2011","journal-title":"J Hosp Infect"},{"key":"2020110410412589300_CIW326C11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2307\/30142377","article-title":"An outbreak of cutaneous aspergillosis in a tertiary-care hospital","volume":"17","author":"Bryce","year":"1996","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020110410412589300_CIW326C12","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1086\/342305","article-title":"Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds","volume":"35","author":"Anaissie","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1086\/338958","article-title":"Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study","volume":"34","author":"Anaissie","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood-2002-02-0530","article-title":"Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies","volume":"101","author":"Anaissie","year":"2003","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C15","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1086\/324501","article-title":"Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections","volume":"33","author":"Anaissie","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-13-289","article-title":"The water supply system as a potential source of fungal infection in paediatric haematopoietic stem cell units","volume":"13","author":"Mesquita-Rocha","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2020110410412589300_CIW326C17","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1128\/JCM.41.9.4101-4106.2003","article-title":"Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains","volume":"41","author":"Warris","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020110410412589300_CIW326C19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11046-009-9247-z","article-title":"Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients","volume":"168","author":"Partridge-Hinckley","year":"2009","journal-title":"Mycopathologia"},{"key":"2020110410412589300_CIW326C20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1086\/501691","article-title":"Refinements of environmental assessment during an outbreak investigation of invasive aspergillosis in a leukemia and bone marrow transplant unit","volume":"21","author":"Thio","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020110410412589300_CIW326C21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1086\/502101","article-title":"Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies","volume":"23","author":"Hahn","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020110410412589300_CIW326C22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1432-2277.2006.00411.x","article-title":"Outbreak of aspergillosis infections among lung transplant recipients","volume":"20","author":"Raviv","year":"2007","journal-title":"Transpl Int"},{"key":"2020110410412589300_CIW326C23","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/cid\/cir771","article-title":"Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit","volume":"54","author":"Pelaez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bmt.2009.261","article-title":"Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated","volume":"44","author":"Yokoe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"van der Linden","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1086\/341318","article-title":"Prevention of nosocomial fungal infection: the French approach","volume":"35","author":"Gangneux","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/322970","article-title":"Counterpoint: invasive aspergillosis and the environment--rethinking our approach to prevention","volume":"33","author":"Hajjeh","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00005792-199201000-00003","article-title":"Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death","volume":"71","author":"Weinberger","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"key":"2020110410412589300_CIW326C30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1700737","article-title":"Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients","volume":"19","author":"Jantunen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C32","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C33","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","article-title":"Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease","volume":"13","author":"van Burik","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020110410412589300_CIW326C34","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMoa0802629","article-title":"Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation","volume":"359","author":"Bochud","year":"2008","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C35","doi-asserted-by":"crossref","first-page":"e1000101","DOI":"10.1371\/journal.pgen.1000101","article-title":"Plasminogen alleles influence susceptibility to invasive aspergillosis","volume":"4","author":"Zaas","year":"2008","journal-title":"PLoS Genet"},{"key":"2020110410412589300_CIW326C36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1211161","article-title":"Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation","volume":"370","author":"Cunha","year":"2014","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C37","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2010-04-279307","article-title":"Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity","volume":"116","author":"Cunha","year":"2010","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C38","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/cid\/civ386","article-title":"PTX3 polymorphisms and invasive mold infections after solid organ transplant","volume":"61","author":"Wojtowicz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C39","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jiu636","article-title":"IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation","volume":"211","author":"Wojtowicz","year":"2015","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C40","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C41","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/ajt.12691","article-title":"Epidemiology of invasive mold infections in lung transplant recipients","volume":"14","author":"Doligalski","year":"2014","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1399-3062.2010.00492.x","article-title":"Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients","volume":"12","author":"Neofytos","year":"2010","journal-title":"Transpl Infect Dis"},{"issue":"suppl 4","key":"2020110410412589300_CIW326C43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ajt.12115","article-title":"Aspergillosis in solid organ transplantation","volume":"13","author":"Singh","year":"2013","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.TP.0000437434.42851.d4","article-title":"Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis","volume":"97","author":"Luong","year":"2014","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/RHU.0b013e31819e67b1","article-title":"Invasive pulmonary aspergillosis in patients with antineutrophil cytoplasmic antibody associated vasculitis","volume":"15","author":"Su","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"2020110410412589300_CIW326C46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.114.1.251","article-title":"Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases","volume":"114","author":"Mylonakis","year":"1998","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1378\/chest.114.1.131","article-title":"Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group","volume":"114","author":"Wallace","year":"1998","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C48","doi-asserted-by":"crossref","first-page":"e5234","DOI":"10.1371\/journal.pone.0005234","article-title":"Chronic granulomatous disease: the European experience","volume":"4","author":"van den Berg","year":"2009","journal-title":"PLoS One"},{"key":"2020110410412589300_CIW326C49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-199809000-00004","article-title":"Aspergillus nidulans infection in chronic granulomatous disease","volume":"77","author":"Segal","year":"1998","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C51","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1086\/430068","article-title":"Posaconazole as salvage therapy in patients with chronic granulomatous disease with invasive filamentous fungal infection","volume":"40","author":"Segal","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C52","first-page":"CD008078","article-title":"Alemtuzumab for patients with chronic lymphocytic leukaemia","volume":"2","author":"Skoetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410412589300_CIW326C53","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C54","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C55","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2020110410412589300_CIW326C56","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020110410412589300_CIW326C57","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2003-01-0267","article-title":"Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study","volume":"102","author":"Marty","year":"2003","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C58","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"Meersseman","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C61","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive Care Med"},{"key":"2020110410412589300_CIW326C62","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3201\/eid1606.100165","article-title":"Invasive aspergillosis after pandemic (H1N1) 2009","volume":"16","author":"Lat","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"2020110410412589300_CIW326C63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-13-29","article-title":"Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes","volume":"13","author":"Baddley","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2020110410412589300_CIW326C64","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C65","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1309\/AJCP99OOOZSNISCZ","article-title":"Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution","volume":"131","author":"Sangoi","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"2020110410412589300_CIW326C66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1309\/AJCPO8VTSK3HRNUT","article-title":"Diagnostic accuracy of histopathologic and cytopathologic examination of Aspergillus species","volume":"139","author":"Shah","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2020110410412589300_CIW326C67","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1309\/EXBVYAUPENBM285Y","article-title":"Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination","volume":"119","author":"Tarrand","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2020110410412589300_CIW326C68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.00053-10","article-title":"Histopathologic diagnosis of fungal infections in the 21st century","volume":"24","author":"Guarner","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"2020110410412589300_CIW326C69","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/jclinpath-2011-200500","article-title":"From the patient to the clinical mycology laboratory: how can we optimise microscopy and culture methods for mould identification?","volume":"65","author":"Vyzantiadis","year":"2012","journal-title":"J Clin Pathol"},{"key":"2020110410412589300_CIW326C70","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(05)70238-3","article-title":"Laboratory diagnosis of invasive aspergillosis","volume":"5","author":"Hope","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2020110410412589300_CIW326C71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1473-3099(03)00580-2","article-title":"British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections","volume":"3","author":"Denning","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2020110410412589300_CIW326C72","doi-asserted-by":"crossref","first-page":"459405","DOI":"10.1155\/2013\/459405","article-title":"Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome","volume":"2013","author":"Barton","year":"2013","journal-title":"Scientifica"},{"key":"2020110410412589300_CIW326C73","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1128\/JCM.36.12.3683-3685.1998","article-title":"Critical evaluation of 4-week incubation for fungal cultures: is the fourth week useful?","volume":"36","author":"Labarca","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C74","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1034\/j.1399-3003.2000.15b30.x","article-title":"Diagnosis of pulmonary aspergillosis using optical brighteners","volume":"15","author":"Andreas","year":"2000","journal-title":"Eur Respir J"},{"key":"2020110410412589300_CIW326C75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1439-0507.1993.tb00758.x","article-title":"Evaluation of Calcofluor staining in the diagnosis of fungal corneal ulcer","volume":"36","author":"Chander","year":"1993","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C76","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10096-011-1229-7","article-title":"A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility","volume":"30","author":"Mortensen","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C77","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/JCM.01365-14","article-title":"PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance","volume":"52","author":"Arvanitis","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C78","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1128\/JCM.00942-12","article-title":"Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review","volume":"50","author":"Avni","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C79","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/1040841X.2013.804033","article-title":"Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis","volume":"41","author":"Heng","year":"2015","journal-title":"Crit Rev Microbiol"},{"key":"2020110410412589300_CIW326C80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2020110410412589300_CIW326C81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/myc.12103","article-title":"Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR","volume":"57","author":"Fraczek","year":"2014","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C83","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2013.04.007","article-title":"Novel immunologic classification of aspergillosis in adult cystic fibrosis","volume":"132","author":"Baxter","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2020110410412589300_CIW326C84","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/thoraxjnl-2012-202412","article-title":"Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum","volume":"68","author":"Baxter","year":"2013","journal-title":"Thorax"},{"key":"2020110410412589300_CIW326C85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cir179","article-title":"High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease","volume":"52","author":"Denning","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mimet.2011.01.024","article-title":"Homogenisation of cystic fibrosis sputum by sonication\u2014an essential step for Aspergillus PCR","volume":"85","author":"Baxter","year":"2011","journal-title":"J Microbiol Methods"},{"key":"2020110410412589300_CIW326C87","doi-asserted-by":"crossref","first-page":"e56706","DOI":"10.1371\/journal.pone.0056706","article-title":"Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis","volume":"8","author":"Reinwald","year":"2013","journal-title":"PLoS One"},{"key":"2020110410412589300_CIW326C88","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/JCM.02387-13","article-title":"Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities","volume":"51","author":"Reinwald","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C89","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1111\/1469-0691.12110","article-title":"Efficacy of DNA amplification in tissue biopsy samples to improve the detection of invasive fungal disease","volume":"19","author":"Buitrago","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C90","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2002.07.004","article-title":"Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients","volume":"7","author":"Herbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C91","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/422009","article-title":"Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance","volume":"190","author":"Marr","year":"2004","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C92","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/430826","article-title":"Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C93","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1086\/343804","article-title":"Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients","volume":"186","author":"Maertens","year":"2002","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C94","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/514349","article-title":"Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay","volume":"44","author":"Maertens","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C95","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C96","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C97","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/00365548.2012.657672","article-title":"Diagnostic value of the serum galactomannan assay for invasive aspergillosis: it is less useful in non-haematological patients","volume":"44","author":"Ku","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"2020110410412589300_CIW326C98","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/TP.0b013e31819288d5","article-title":"False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients","volume":"87","author":"Fortun","year":"2009","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C99","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/JCM.42.1.435-438.2004","article-title":"Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients","volume":"42","author":"Kwak","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C100","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1600-6143.2004.00415.x","article-title":"Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients","volume":"4","author":"Husain","year":"2004","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C101","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1128\/JCM.38.10.3900-3901.2000","article-title":"Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasve aspergillosis","volume":"38","author":"Verweij","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C102","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/j.1439-0507.2009.01835.x","article-title":"Successful management of invasive aspergillosis presenting as pericarditis in an adult patient with chronic granulomatous disease","volume":"54","author":"Mortensen","year":"2011","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejrad.2008.03.026","article-title":"Correlation between high-resolution computed tomography and galactomannan antigenemia in adult hematologic patients at risk for invasive aspergillosis","volume":"71","author":"Hidalgo","year":"2009","journal-title":"Eur J Radiol"},{"key":"2020110410412589300_CIW326C104","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/INF.0b013e3180616cbb","article-title":"Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients","volume":"26","author":"Steinbach","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410412589300_CIW326C105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/INF.0b013e31817197ab","article-title":"Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis","volume":"27","author":"Hayden","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410412589300_CIW326C106","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1469-0691.2009.03065.x","article-title":"Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation","volume":"16","author":"Castagnola","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jpids\/pis044","article-title":"Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients","volume":"1","author":"Fisher","year":"2012","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020110410412589300_CIW326C108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmii.2013.12.003","article-title":"Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children","volume":"49","author":"Dinand","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"2020110410412589300_CIW326C109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pbc.24363","article-title":"Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients","volume":"60","author":"Choi","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2020110410412589300_CIW326C110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/myc.12048","article-title":"Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies","volume":"56","author":"Jha","year":"2013","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C111","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3855\/jidc.2110","article-title":"Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients","volume":"6","author":"Badiee","year":"2012","journal-title":"J Infect Dev Ctries"},{"key":"2020110410412589300_CIW326C112","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1093\/cid\/cir027","article-title":"Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma","volume":"52","author":"Park","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C113","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jinf.2014.01.005","article-title":"Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis","volume":"68","author":"Shin","year":"2014","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11046-012-9531-1","article-title":"The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD)","volume":"174","author":"Aquino","year":"2012","journal-title":"Mycopathologia"},{"key":"2020110410412589300_CIW326C115","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/13693786.2012.676739","article-title":"Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species","volume":"50","author":"Warren","year":"2012","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C116","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1469-0691.2008.02122.x","article-title":"Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis","volume":"15","author":"Cordonnier","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C117","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/mmy\/myv034","article-title":"Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1--&gt;3)-beta-D-glucan in experimental invasive pulmonary aspergillosis","volume":"53","author":"Petraitiene","year":"2015","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C118","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/JCM.00285-14","article-title":"Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States","volume":"52","author":"Vergidis","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C119","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1128\/JCM.43.8.3925-3931.2005","article-title":"Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity","volume":"43","author":"Mennink-Kersten","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C120","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJM200312113492424","article-title":"False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam","volume":"349","author":"Sulahian","year":"2003","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C121","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(04)01045-X","article-title":"Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis","volume":"4","author":"Mennink-Kersten","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"2020110410412589300_CIW326C122","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0140-6736(03)15393-7","article-title":"Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection","volume":"363","author":"Mennink-Kersten","year":"2004","journal-title":"Lancet"},{"key":"2020110410412589300_CIW326C123","doi-asserted-by":"crossref","first-page":"e65776","DOI":"10.1371\/journal.pone.0065776","article-title":"Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model","volume":"8","author":"Schwarzinger","year":"2013","journal-title":"PLoS One"},{"key":"2020110410412589300_CIW326C124","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective anti-mold prophylaxis","volume":"59","author":"Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C125","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/CVI.00226-08","article-title":"Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid","volume":"15","author":"Husain","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"2020110410412589300_CIW326C126","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1128\/JCM.42.12.5517-5522.2004","article-title":"Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid","volume":"42","author":"Musher","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C127","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1086\/647935","article-title":"Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases","volume":"49","author":"Maertens","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C128","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/JCM.06423-11","article-title":"Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity","volume":"50","author":"D'Haese","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C129","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/432470","article-title":"Multicenter clinical evaluation of the (1--&gt;3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans","volume":"41","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C131","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/AAC.00658-06","article-title":"Reactivity of (1--&gt;3)-beta-D-glucan assay with commonly used intravenous antimicrobials","volume":"50","author":"Marty","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C132","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C133","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/JCM.03567-13","article-title":"Use and limits of (1\u20133)-beta-D-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis","volume":"52","author":"Sulahian","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C134","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/JCM.00506-08","article-title":"Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients","volume":"47","author":"Hachem","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/JCM.43.1.299-305.2005","article-title":"Contribution of (1-&gt;3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan","volume":"43","author":"Pazos","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C136","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C137","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2141.2003.04308.x","article-title":"Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis","volume":"121","author":"Becker","year":"2003","journal-title":"Br J Haematol"},{"key":"2020110410412589300_CIW326C138","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1034\/j.1600-0455.2002.430310.x","article-title":"Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis","volume":"43","author":"Hauggaard","year":"2002","journal-title":"Acta Radiol"},{"key":"2020110410412589300_CIW326C139","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/cid\/civ154","article-title":"High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies","volume":"60","author":"Stanzani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C140","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.transproceed.2006.02.072","article-title":"Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation","volume":"38","author":"Busca","year":"2006","journal-title":"Transplant Proc"},{"key":"2020110410412589300_CIW326C141","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/444462","article-title":"Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies","volume":"41","author":"Weisser","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C142","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1997.15.1.139","article-title":"Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery","volume":"15","author":"Caillot","year":"1997","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C143","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1086\/657065","article-title":"Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C144","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3760\/cma.j.issn.0366-6999.2011.20.08","article-title":"Pulmonary fungal infections after bone marrow transplantation: the value of high-resolution computed tomography in predicting their etiology","volume":"124","author":"Li","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"2020110410412589300_CIW326C145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C146","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/RTI.0b013e31805f6a42","article-title":"Comparison of CT features of Aspergillus and bacterial pneumonia in severely neutropenic patients","volume":"22","author":"Bruno","year":"2007","journal-title":"J Thorac Imaging"},{"key":"2020110410412589300_CIW326C147","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hon.879","article-title":"Radiological findings of early invasive pulmonary aspergillosis in immune-compromised patients","volume":"27","author":"Brook","year":"2009","journal-title":"Hematol Oncol"},{"key":"2020110410412589300_CIW326C148","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/cit929","article-title":"The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?","volume":"58","author":"Legouge","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C149","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1086\/587991","article-title":"Reversed halo sign in invasive pulmonary fungal infections","volume":"46","author":"Wahba","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C150","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C151","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4187\/respcare.03020","article-title":"Reversed halo sign: a systematic review","volume":"59","author":"Maturu","year":"2014","journal-title":"Respir Care"},{"key":"2020110410412589300_CIW326C152","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2011-04-351601","article-title":"The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies","volume":"119","author":"Bergeron","year":"2012","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C153","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1378\/chest.106.4.1156","article-title":"Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis","volume":"106","author":"Blum","year":"1994","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C154","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-1331.2007.01755.x","article-title":"Relevant imaging findings of cerebral aspergillosis on MRI: a retrospective case-based study in immunocompromised patients","volume":"14","author":"Gabelmann","year":"2007","journal-title":"Eur J Neurol"},{"key":"2020110410412589300_CIW326C155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00062-014-0305-7","article-title":"MRI of CNS fungal infections: review of aspergillosis to histoplasmosis and everything in between","volume":"24","author":"Starkey","year":"2014","journal-title":"Clin Neuroradiol"},{"key":"2020110410412589300_CIW326C156","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1076-6332(03)80166-6","article-title":"Imaging findings in intracranial aspergillosis","volume":"9","author":"Yamada","year":"2002","journal-title":"Acad Radiol"},{"key":"2020110410412589300_CIW326C157","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MD.0b013e318274cd77","article-title":"Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature","volume":"91","author":"Kourkoumpetis","year":"2012","journal-title":"Medicine"},{"key":"2020110410412589300_CIW326C158","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00701-005-0659-3","article-title":"Diagnostic MR imaging features of craniocerebral aspergillosis of sino-nasal origin in immunocompetent patients","volume":"148","author":"Siddiqui","year":"2006","journal-title":"Acta Neurochir (Wien)"},{"key":"2020110410412589300_CIW326C159","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C160","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1002\/cncr.25905","article-title":"Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study","volume":"117","author":"Sampsonas","year":"2011","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C161","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.ejca.2009.05.001","article-title":"Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology","volume":"45","author":"Maschmeyer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020110410412589300_CIW326C162","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1378\/chest.118.6.1739","article-title":"Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy","volume":"118","author":"Pereira Gomes","year":"2000","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C163","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.rmed.2007.05.017","article-title":"Diagnostic accuracy of bronchoalveolar lavage samples in immunosuppressed patients with suspected pneumonia: analysis of a protocol","volume":"101","author":"Velez","year":"2007","journal-title":"Respir Med"},{"key":"2020110410412589300_CIW326C164","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/LBR.0000000000000042","article-title":"Survey of academic pulmonologists, oncologists, and infectious disease physicians on the role of bronchoscopy in managing hematopoietic stem cell transplantation patients with pulmonary infiltrates","volume":"21","author":"Wahla","year":"2014","journal-title":"J Bronchology Interv Pulmonol"},{"issue":"suppl 3","key":"2020110410412589300_CIW326C165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2011-200713","article-title":"British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults","volume":"66","author":"Du Rand","year":"2011","journal-title":"Thorax"},{"key":"2020110410412589300_CIW326C166","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1399-3003.1999.14b01.x","article-title":"Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL","volume":"14","author":"Haslam","year":"1999","journal-title":"Eur Respir J"},{"key":"2020110410412589300_CIW326C167","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C168","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/JCM.01940-06","article-title":"Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid","volume":"45","author":"Hage","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C169","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-991520","article-title":"Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure","volume":"28","author":"Baughman","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4103\/1817-1737.114302","article-title":"Association of bronchoalveolar lavage yield with chest computed tomography findings and symptoms in immunocompromised patients","volume":"8","author":"Brownback","year":"2013","journal-title":"Ann Thorac Med"},{"key":"2020110410412589300_CIW326C171","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2020110410412589300_CIW326C172","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C173","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cid\/cis972","article-title":"The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B","volume":"56","author":"Farmakiotis","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C174","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C175","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C176","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","article-title":"Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation","volume":"40","author":"Borro","year":"2008","journal-title":"Transplant Proc"},{"key":"2020110410412589300_CIW326C177","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C178","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0022-3859.128806","article-title":"Role of inhaled amphotericin in allergic bronchopulmonary aspergillosis","volume":"60","author":"Sehgal","year":"2014","journal-title":"J Postgrad Med"},{"key":"2020110410412589300_CIW326C179","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/phar.1309","article-title":"Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation","volume":"33","author":"Safdar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2020110410412589300_CIW326C180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1399-3062.2011.00661.x","article-title":"Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis","volume":"14","author":"Nihtinen","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C181","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/bmt.2010.76","article-title":"Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study","volume":"46","author":"Morello","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C182","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","article-title":"Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety","volume":"28","author":"Monforte","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"2020110410412589300_CIW326C183","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"suppl 2","key":"2020110410412589300_CIW326C184","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0924-8579(08)70019-0","article-title":"Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B","volume":"32","author":"Sole","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410412589300_CIW326C185","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"2020110410412589300_CIW326C186","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C187","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C188","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.05193-11","article-title":"Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people","volume":"55","author":"Hall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C189","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"Wurthwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C190","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C191","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer Study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C192","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C193","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jinf.2010.08.005","article-title":"Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan","volume":"61","author":"Kohno","year":"2010","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C194","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C195","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s10096-010-1013-0","article-title":"Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort","volume":"29","author":"Hiemenz","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C196","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C197","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","author":"Maertens","year":"2006","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C198","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C199","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1345\/aph.10262","article-title":"Intravenous itraconazole","volume":"35","author":"Slain","year":"2001","journal-title":"Ann Pharmacother"},{"key":"2020110410412589300_CIW326C200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"2020110410412589300_CIW326C201","first-page":"69","article-title":"Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study","volume":"20","author":"Lazo de la Vega","year":"1994","journal-title":"Drugs Exp Clin Res"},{"key":"2020110410412589300_CIW326C202","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-013-1826-x","article-title":"The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"2020110410412589300_CIW326C204","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/jac\/dkr233","article-title":"Peripheral neuropathy in patients on long-term triazole antifungal therapy","volume":"66","author":"Baxter","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C205","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C206","first-page":"367","article-title":"Cyclodextrin nephrosis in the rat","volume":"83","author":"Frank","year":"1976","journal-title":"Am J Pathol"},{"key":"2020110410412589300_CIW326C207","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)","volume":"99","author":"Luke","year":"2010","journal-title":"J Pharm Sci"},{"key":"2020110410412589300_CIW326C208","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2020110410412589300_CIW326C209","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"key":"2020110410412589300_CIW326C210","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3947\/ic.2013.45.4.406","article-title":"Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population","volume":"45","author":"Kim","year":"2013","journal-title":"Infect Chemother"},{"key":"2020110410412589300_CIW326C211","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C212","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/pgs.11.18","article-title":"Pharmacogenomics of the triazole antifungal agent voriconazole","volume":"12","author":"Mikus","year":"2011","journal-title":"Pharmacogenomics"},{"key":"2020110410412589300_CIW326C213","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410412589300_CIW326C214","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C215","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C216","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C217","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C218","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C219","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C220","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","article-title":"Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity","volume":"56","author":"Mitsani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C221","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"2020110410412589300_CIW326C222","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C223","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"2020110410412589300_CIW326C224","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"2020110410412589300_CIW326C225","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"2020110410412589300_CIW326C226","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C227","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C228","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann Pharmacother"},{"key":"2020110410412589300_CIW326C229","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2020110410412589300_CIW326C230","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jac\/dkl108","article-title":"Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections","volume":"57","author":"den Hollander","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C231","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1600-6143.2012.04042.x","article-title":"Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients","volume":"12","author":"Luong","year":"2012","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C232","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000319032","article-title":"Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation","volume":"64","author":"Wu","year":"2010","journal-title":"Eur Neurol"},{"key":"2020110410412589300_CIW326C233","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/11316480-000000000-00000","article-title":"Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions","volume":"26","author":"Kuypers","year":"2009","journal-title":"Drugs Aging"},{"key":"2020110410412589300_CIW326C234","first-page":"10","article-title":"Voriconazole-induced periostitis in two post-transplant patients","volume":"7","author":"Bucknor","year":"2013","journal-title":"J Radiol Case Rep"},{"key":"2020110410412589300_CIW326C235","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.3928\/01477447-20110922-35","article-title":"Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient","volume":"34","author":"Lustenberger","year":"2011","journal-title":"Orthopedics"},{"key":"2020110410412589300_CIW326C236","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/ciu513","article-title":"Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain","volume":"59","author":"Moon","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C237","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/j.1600-6143.2009.02837.x","article-title":"Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients","volume":"9","author":"Wang","year":"2009","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C238","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciq188","article-title":"Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy","volume":"52","author":"Wermers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C239","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","article-title":"Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole","volume":"120","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C240","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.05275-11","article-title":"Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles","volume":"56","author":"Thompson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C241","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/tid.12063","article-title":"Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart\/lung transplant patients","volume":"15","author":"McLaughlin","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C242","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2020110410412589300_CIW326C243","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1524-4725.2012.02418.x","article-title":"Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation","volume":"38","author":"Zwald","year":"2012","journal-title":"Dermatol Surg"},{"key":"2020110410412589300_CIW326C244","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increased serum levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C245","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/myc.12339","article-title":"Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C246","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/AAC.00581-15","article-title":"Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies","volume":"59","author":"Cumpston","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C247","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1128\/AAC.01489-12","article-title":"Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients","volume":"56","author":"Sanchez-Ortega","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C248","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C249","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C250","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C251","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2010.11.021","article-title":"A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis","volume":"37","author":"Bryant","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410412589300_CIW326C252","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/AAC.01671-10","article-title":"Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration","volume":"55","author":"Lignell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C253","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C254","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C255","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C256","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C257","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C258","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect Drug Resist"},{"key":"2020110410412589300_CIW326C259","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/17425255.2012.683859","article-title":"Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections","volume":"8","author":"Livermore","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2020110410412589300_CIW326C260","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C261","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/17425255.2011.627854","article-title":"Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450","volume":"7","author":"Gubbins","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2020110410412589300_CIW326C262","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/bmt.2011.146","article-title":"Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics","volume":"47","author":"Ashbee","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C263","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxlet.2011.01.027","article-title":"Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition","volume":"202","author":"Dvorak","year":"2011","journal-title":"Toxicol Lett"},{"key":"2020110410412589300_CIW326C264","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/CMR.00059-05","article-title":"Human pharmacogenomic variations and their implications for antifungal efficacy","volume":"19","author":"Meletiadis","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2020110410412589300_CIW326C265","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002018-199818020-00001","article-title":"Systemic antifungal agents. Drug interactions of clinical significance","volume":"18","author":"Albengres","year":"1998","journal-title":"Drug Saf"},{"key":"2020110410412589300_CIW326C266","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2020110410412589300_CIW326C267","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1358\/dot.2003.39.10.799473","article-title":"Clinical impact of drug-drug interactions with systemic azole antifungals","volume":"39","author":"Bates","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"2020110410412589300_CIW326C268","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/j.1875-9114.1998.tb03152.x","article-title":"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports","volume":"18","author":"Chan","year":"1998","journal-title":"Pharmacotherapy"},{"key":"2020110410412589300_CIW326C269","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(93)90317-I","article-title":"Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine","volume":"95","author":"Crane","year":"1993","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C270","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1128\/AAC.00184-09","article-title":"In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes","volume":"53","author":"Dannaoui","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C271","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pds.1473","article-title":"Drug-drug interactions with systemic antifungals in clinical practice","volume":"16","author":"Depont","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020110410412589300_CIW326C272","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2710.2007.00812.x","article-title":"Inherited long QT syndrome revealed by antifungals drug-drug interaction","volume":"32","author":"Eiden","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"2020110410412589300_CIW326C273","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.166.9.1009","article-title":"Reducing warfarin medication interactions: an interrupted time series evaluation","volume":"166","author":"Feldstein","year":"2006","journal-title":"Arch Intern Med"},{"key":"2020110410412589300_CIW326C274","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QCO.0b013e3282f1be91","article-title":"Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients","volume":"20","author":"Gubbins","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"2020110410412589300_CIW326C275","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1111\/j.1399-0012.2010.01373.x","article-title":"Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction","volume":"25","author":"Kramer","year":"2011","journal-title":"Clin Transplant"},{"key":"2020110410412589300_CIW326C276","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkq020","article-title":"In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes","volume":"65","author":"Narreddy","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C277","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/138920009788499012","article-title":"Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care","volume":"10","author":"Nivoix","year":"2009","journal-title":"Curr Drug Metab"},{"key":"2020110410412589300_CIW326C278","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/088800101753328529","article-title":"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature","volume":"18","author":"Sathiapalan","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"key":"2020110410412589300_CIW326C279","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.48.5.1664-1669.2004","article-title":"In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2125.2003.01995.x","article-title":"Voriconazole potentiates warfarin-induced prothrombin time prolongation","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2020110410412589300_CIW326C281","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C282","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2020110410412589300_CIW326C283","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C284","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C285","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C286","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/j.jinf.2007.07.019","article-title":"Random plasma concentrations of voriconazole decline over time","volume":"55","author":"Mulanovich","year":"2007","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C287","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C288","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C289","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1128\/AAC.00700-12","article-title":"Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections","volume":"56","author":"Boyd","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C290","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C291","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C292","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C293","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C294","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C295","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/CMR.18.1.163-194.2005","article-title":"Combination treatment of invasive fungal infections","volume":"18","author":"Mukherjee","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2020110410412589300_CIW326C296","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s11908-008-0076-x","article-title":"Combination antifungal therapy: from bench to bedside","volume":"10","author":"Wirk","year":"2008","journal-title":"Curr Infect Dis Rep"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C297","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.3109\/13693786.2010.499374","article-title":"Newer combination antifungal therapies for invasive aspergillosis","volume":"49","author":"Steinbach","year":"2011","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C298","first-page":"99","article-title":"Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies","volume":"6","author":"Zhang","year":"2014","journal-title":"J Thorac Dis"},{"key":"2020110410412589300_CIW326C299","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/cid\/ciu581","article-title":"Antifungal combination therapy for invasive aspergillosis","volume":"59","author":"Martin-Pena","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C300","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/151.5.902","article-title":"The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis","volume":"151","author":"Schaffner","year":"1985","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C301","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1439-0507.1993.tb00732.x","article-title":"Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism","volume":"36","author":"Schaffner","year":"1993","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C302","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s101560050021","article-title":"Effect of sequential combination of amphotericin B and azole antifungal agents against Aspergillus fumigatus","volume":"5","author":"Maesaki","year":"1999","journal-title":"J Infect Chemother"},{"key":"2020110410412589300_CIW326C303","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.46.10.3208-3214.2002","article-title":"Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis","volume":"46","author":"Lewis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"2020110410412589300_CIW326C304","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1086\/376524","article-title":"Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001","volume":"37","author":"Steinbach","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C305","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","article-title":"Combination antifungal therapy","volume":"48","author":"Johnson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C306","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1128\/AAC.50.4.1567-1569.2006","article-title":"Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis","volume":"50","author":"Kirkpatrick","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C307","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijantimicag.2006.07.011","article-title":"The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions","volume":"28","author":"Meletiadis","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410412589300_CIW326C308","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/506617","article-title":"Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation","volume":"194","author":"Meletiadis","year":"2006","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C309","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis","volume":"53","author":"Petraitis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13693780500148350","article-title":"Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis","volume":"44","author":"Clemons","year":"2006","journal-title":"Med Mycol"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C311","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1080\/13693780802428542","article-title":"Paradoxical echinocandin activity: a limited in vitro phenomenon?","volume":"47","author":"Wiederhold","year":"2009","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C312","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drup.2009.09.002","article-title":"Azole-resistance in Aspergillus: proposed nomenclature and breakpoints","volume":"12","author":"Verweij","year":"2009","journal-title":"Drug Resist Updat"},{"key":"2020110410412589300_CIW326C313","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/phar.1233","article-title":"The evolving role of antifungal susceptibility testing","volume":"33","author":"Eschenauer","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2020110410412589300_CIW326C314","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C315","article-title":"Reference method for broth dilution antifungal susceptibility testing for filamentous fungi","author":"Clinical and Laboratory Standards Institute","year":"2008","edition":"2nd ed"},{"key":"2020110410412589300_CIW326C316","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1469-0691.2003.00592.x","article-title":"Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST)","volume":"9","author":"Cuenca-Estrella","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C317","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C318","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C319","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/JCM.02136-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06795.x","article-title":"The impact of azole resistance on aspergillosis guidelines","volume":"1272","author":"Georgiadou","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"2020110410412589300_CIW326C321","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1358\/dnp.2010.23.2.1400855","article-title":"EUCAST breakpoints for antifungals","volume":"23","author":"Rodriguez-Tudela","year":"2010","journal-title":"Drug News Perspect"},{"key":"2020110410412589300_CIW326C322","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dku023","article-title":"Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"69","author":"Siopi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C323","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","article-title":"Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp","volume":"16","author":"Arendrup","year":"2013","journal-title":"Drug Resist Updat"},{"key":"2020110410412589300_CIW326C324","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","article-title":"Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/fgbi.2000.1228","article-title":"Phylogenetic species recognition and species concepts in fungi","volume":"31","author":"Taylor","year":"2000","journal-title":"Fungal Genet Biol"},{"key":"2020110410412589300_CIW326C326","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of Aspergillus","volume":"178","author":"Alastruey-Izquierdo","year":"2014","journal-title":"Mycopathologia"},{"key":"2020110410412589300_CIW326C327","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/dkh507","article-title":"Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma","volume":"55","author":"Chen","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C328","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1128\/AAC.47.3.1120-1124.2003","article-title":"A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus","volume":"47","author":"Diaz-Guerra","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C329","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2006.08.017","article-title":"Multi-azole resistance in Aspergillus fumigatus","volume":"28","author":"Howard","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"2020110410412589300_CIW326C330","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.48.7.2747-2750.2004","article-title":"Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs","volume":"48","author":"Mellado","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C331","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C332","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/AAC.47.5.1719-1726.2003","article-title":"Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole","volume":"47","author":"Nascimento","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C333","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJMc061720","article-title":"Multiple-triazole-resistant aspergillosis","volume":"356","author":"Verweij","year":"2007","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C334","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00517-11","article-title":"Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter","volume":"55","author":"Albarrag","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C335","doi-asserted-by":"crossref","first-page":"e50034","DOI":"10.1371\/journal.pone.0050034","article-title":"Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing","volume":"7","author":"Camps","year":"2012","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C336","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.3109\/13693786.2010.508469","article-title":"Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection","volume":"49","author":"Howard","year":"2011","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C337","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diagmicrobio.2013.04.022","article-title":"Differential expression of ATP-binding cassette and\/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus","volume":"76","author":"Natesan","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C338","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/AAC.01189-10","article-title":"Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity","volume":"55","author":"Rajendran","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C339","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1087-1845(02)00016-6","article-title":"Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate","volume":"36","author":"Slaven","year":"2002","journal-title":"Fungal Genet Biol"},{"issue":"suppl 6","key":"2020110410412589300_CIW326C340","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1469-0691.12513","article-title":"Update on antifungal resistance in Aspergillus and Candida","volume":"20","author":"Arendrup","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 6","key":"2020110410412589300_CIW326C341","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/1469-0691.12495","article-title":"Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside","volume":"20","author":"Cuenca-Estrella","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C342","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Alastruey-Izquierdo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C343","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Baddley","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C344","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/AAC.00692-10","article-title":"Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain","volume":"54","author":"Mortensen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C345","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1371\/journal.pmed.0050219","article-title":"Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism","volume":"5","author":"Snelders","year":"2008","journal-title":"PLoS Med"},{"key":"2020110410412589300_CIW326C346","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2020110410412589300_CIW326C347","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2020110410412589300_CIW326C348","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C349","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2020110410412589300_CIW326C350","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/cncr.23311","article-title":"Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy","volume":"112","author":"Hachem","year":"2008","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C351","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1705143","article-title":"Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA)","volume":"36","author":"Ito","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C352","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100960000437","article-title":"Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients","volume":"20","author":"Herbrecht","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C353","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1034\/j.1399-0012.2000.140409.x","article-title":"Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections","volume":"14","author":"Linden","year":"2000","journal-title":"Clin Transplant"},{"key":"2020110410412589300_CIW326C354","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C355","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","article-title":"Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin","volume":"97","author":"Aliff","year":"2003","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C356","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C357","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","article-title":"Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis","volume":"46","author":"Kirkpatrick","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C358","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin","volume":"187","author":"Petraitis","year":"2003","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C359","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ijid.2011.10.004","article-title":"The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review","volume":"16","author":"Garbati","year":"2012","journal-title":"Int J Infect Dis"},{"key":"2020110410412589300_CIW326C360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/myc.12161","article-title":"Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study","volume":"57","author":"Candoni","year":"2014","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C361","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C362","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020110410412589300_CIW326C363","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270005281234","article-title":"Safety and pharmacokinetics of coadministered voriconazole and anidulafungin","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2020110410412589300_CIW326C364","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/13693786.2012.693213","article-title":"Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)","volume":"51","author":"Jarque","year":"2013","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-783X-17-7","article-title":"Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry","volume":"17","author":"Egerer","year":"2012","journal-title":"Eur J Med Res"},{"key":"2020110410412589300_CIW326C366","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2334-10-182","article-title":"Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry","volume":"10","author":"Maertens","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2020110410412589300_CIW326C367","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study","volume":"95","author":"Cordonnier","year":"2010","journal-title":"Haematologica"},{"key":"2020110410412589300_CIW326C368","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.bbmt.2014.04.016","article-title":"Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis","volume":"20","author":"Liu","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020110410412589300_CIW326C369","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C370","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C371","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C372","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.6004\/jnccn.2013.0148","article-title":"Myeloid growth factors","volume":"11","author":"Crawford","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"2020110410412589300_CIW326C373","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1189\/jlb.70.6.868","article-title":"In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages","volume":"70","author":"Brummer","year":"2001","journal-title":"J Leukoc Biol"},{"key":"2020110410412589300_CIW326C374","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0928-8244(03)00230-X","article-title":"Polyene and cytokine treatment of experimental aspergillosis","volume":"39","author":"Sionov","year":"2003","journal-title":"FEMS Immunol Med Microbiol"},{"key":"2020110410412589300_CIW326C375","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jac\/dki252","article-title":"Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF","volume":"56","author":"Sionov","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C376","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.00760-07","article-title":"Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis","volume":"52","author":"Quezada","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C377","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.V81.7.1883.1883","article-title":"The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis","volume":"81","author":"Bensinger","year":"1993","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C378","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1046\/j.1537-2995.2002.00249.x","article-title":"Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors","volume":"42","author":"Hubel","year":"2002","journal-title":"Transfusion"},{"key":"2020110410412589300_CIW326C379","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood.V95.11.3302","article-title":"Phase I\/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation","volume":"95","author":"Price","year":"2000","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C380","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone treated donors in neutropenic patients with infection","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C381","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/AAC.02533-12","article-title":"Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis","volume":"57","author":"Martinez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C382","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198105143042001","article-title":"Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions","volume":"304","author":"Wright","year":"1981","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C383","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/imm.12362","article-title":"Clinical implications of interferon gamma genetic and epigenetic variants","volume":"143","author":"Smith","year":"2014","journal-title":"Immunology"},{"key":"2020110410412589300_CIW326C384","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2002-01-0265","article-title":"Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies","volume":"100","author":"Hebart","year":"2002","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C385","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C386","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/cncr.20883","article-title":"The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation","volume":"103","author":"Safdar","year":"2005","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C387","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1164\/rccm.201310-1780IM","article-title":"Pulmonary arterial mycotic pseudoaneurysms in a patient with invasive pulmonary aspergillosis. Successful occlusion by coils","volume":"190","author":"Didier","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C388","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/520274","article-title":"Impact of previous aspergillosis on the outcome of bone marrow transplantation","volume":"26","author":"Offner","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C389","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood-2006-03-008706","article-title":"Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C390","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3109\/10428194.2010.500433","article-title":"Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant","volume":"51","author":"El-Cheikh","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2020110410412589300_CIW326C391","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704469","article-title":"Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients","volume":"33","author":"Cordonnier","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C392","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/508455","article-title":"Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection","volume":"43","author":"Almyroudis","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"suppl 6","key":"2020110410412589300_CIW326C393","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1086\/430921","article-title":"Salvage therapy for aspergillosis","volume":"41","author":"Bennett","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C394","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05007.x","article-title":"Toward more effective antifungal therapy: the prospects of combination therapy","volume":"126","author":"Kontoyiannis","year":"2004","journal-title":"Br J Haematol"},{"key":"2020110410412589300_CIW326C395","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.1995.00430100129015","article-title":"Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data","volume":"155","author":"Ng","year":"1995","journal-title":"Arch Intern Med"},{"key":"2020110410412589300_CIW326C396","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C397","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C398","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C399","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C400","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"Maertens","year":"2009","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C401","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1439-0507.2010.02009.x","article-title":"Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients","volume":"54","author":"Park","year":"2011","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C402","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/cid\/cit393","article-title":"The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"57","author":"Fisher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C403","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cir441","article-title":"Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition","volume":"53","author":"Nouer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C404","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.patbio.2011.10.011","article-title":"Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis","volume":"60","author":"Hadrich","year":"2012","journal-title":"Pathol Biol (Paris)"},{"key":"2020110410412589300_CIW326C405","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JCM.02281-09","article-title":"Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis","volume":"48","author":"Koo","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C406","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2014.05.015","article-title":"Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?","volume":"80","author":"Russo","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C407","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13693786.2010.521523","article-title":"Value of consecutive galactomannan determinations for the diagnosis and prognosis of invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease","volume":"49","author":"He","year":"2011","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C408","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3760\/cma.j.issn.0366-6999.20131651","article-title":"Prognostic value of serum galactomannan index in critically ill patients with chronic obstructive pulmonary disease at risk of invasive pulmonary aspergillosis","volume":"127","author":"He","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"2020110410412589300_CIW326C409","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JCM.06513-11","article-title":"Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis","volume":"50","author":"Chai","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C410","doi-asserted-by":"crossref","first-page":"e90176","DOI":"10.1371\/journal.pone.0090176","article-title":"Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis","volume":"9","author":"Chai","year":"2014","journal-title":"PLoS One"},{"key":"2020110410412589300_CIW326C411","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diagmicrobio.2010.03.017","article-title":"Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies","volume":"68","author":"Luong","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C412","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1111\/j.1469-0691.2012.03777.x","article-title":"Post-diagnostic kinetics of the (1 \u2192 3)-\u03b2-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia","volume":"18","author":"Koo","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C413","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C414","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C415","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C416","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C417","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1100\/2011\/865239","article-title":"Tracheobronchial manifestations of Aspergillus infections","volume":"11","author":"Krenke","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"2020110410412589300_CIW326C418","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1378\/chest.121.6.1988","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"121","author":"Soubani","year":"2002","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C419","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases","volume":"12","author":"Denning","year":"1990","journal-title":"Rev Infect Dis"},{"key":"2020110410412589300_CIW326C420","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/clinids\/17.3.344","article-title":"Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS","volume":"17","author":"Kemper","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C421","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/thx.54.11.1047","article-title":"Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF","volume":"54","author":"Boots","year":"1999","journal-title":"Thorax"},{"key":"2020110410412589300_CIW326C422","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-2659.2011.00202.x","article-title":"Isolation of Aspergillus in three 2009 H1N1 influenza patients","volume":"5","author":"Adalja","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"key":"2020110410412589300_CIW326C423","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MD.0b013e31826c2ccf","article-title":"Aspergillus tracheobronchitis: report of 8 cases and review of the literature","volume":"91","author":"Fernandez-Ruiz","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C424","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1164\/ajrccm\/144.3_Pt_1.552","article-title":"Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis","volume":"144","author":"Kramer","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2020110410412589300_CIW326C425","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2006.01548.x","article-title":"Voriconazole prophylaxis in lung transplant recipients","volume":"6","author":"Husain","year":"2006","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C426","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1378\/chest.104.3.681","article-title":"Infection in the transplanted and native lung after single lung transplantation","volume":"104","author":"Horvath","year":"1993","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C427","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C428","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMra1216008","article-title":"Mold infections of the central nervous system","volume":"371","author":"McCarthy","year":"2014","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C429","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1128\/JCM.40.4.1496-1499.2002","article-title":"Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis","volume":"40","author":"Viscoli","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C430","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/cid\/cit073","article-title":"(1\u20133)-beta-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections","volume":"56","author":"Mikulska","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C431","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1128\/JCM.05946-11","article-title":"Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay","volume":"50","author":"Tortorano","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C432","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C433","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/08880010050120863","article-title":"Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia","volume":"17","author":"Ng","year":"2000","journal-title":"Pediatr Hematol Oncol"},{"key":"2020110410412589300_CIW326C434","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.bmt.1700852","article-title":"Resolution of invasive central nervous system aspergillosis in a transplant recipient","volume":"20","author":"Khoury","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C435","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1227\/00006123-199504000-00032","article-title":"Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery\u2014case report and review of the literature","volume":"36","author":"Coleman","year":"1995","journal-title":"Neurosurgery"},{"key":"2020110410412589300_CIW326C436","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jac\/dki288","article-title":"Activity of posaconazole in the treatment of central nervous system fungal infections","volume":"56","author":"Pitisuttithum","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C437","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2169\/internalmedicine.38.829","article-title":"Successful treatment of cerebral aspergillosis with a high oral dose of itraconazole after excisional surgery","volume":"38","author":"Imai","year":"1999","journal-title":"Intern Med"},{"key":"2020110410412589300_CIW326C438","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00365540600951333","article-title":"A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid","volume":"39","author":"Okugawa","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2020110410412589300_CIW326C439","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/srin.2001.29298","article-title":"Intrathecal amphotericin in the management of coccidioidal meningitis","volume":"16","author":"Stevens","year":"2001","journal-title":"Semin Respir Infect"},{"key":"2020110410412589300_CIW326C440","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0300-2977(95)00048-8","article-title":"Spinal epidural abscess due to Aspergillus infection of the vertebrae: report of 3 cases","volume":"48","author":"Dubbeld","year":"1996","journal-title":"Neth J Med"},{"key":"2020110410412589300_CIW326C441","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/09273948.2012.754907","article-title":"Aspergillus terreus endogenous endophthalmitis in a nonimmunocompromised patient with a history of bronchiectasis","volume":"21","author":"Ng","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"key":"2020110410412589300_CIW326C442","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1111\/j.1439-0507.2010.01950.x","article-title":"Inaugural bilateral Aspergillus endophthalmitis in a seriously immunocompromised patient","volume":"54","author":"Georgala","year":"2011","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C443","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.2174\/13816128113199990342","article-title":"Antifungal therapy of aspergillosis of the central nervous system and Aspergillus endophthalmitis","volume":"19","author":"Hoenigl","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2020110410412589300_CIW326C444","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajo.2010.01.024","article-title":"Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis","volume":"149","author":"Shen","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"2020110410412589300_CIW326C445","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00405-007-0281-5","article-title":"Fungus balls of the paranasal sinuses: a review","volume":"264","author":"Grosjean","year":"2007","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2020110410412589300_CIW326C446","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1017\/S0022215109992477","article-title":"Isolated fungus ball mimicking mucocele or frontal sinus tumour: a diagnostic pitfall","volume":"124","author":"Popko","year":"2010","journal-title":"J Laryngol Otol"},{"key":"2020110410412589300_CIW326C447","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.tripleo.2006.12.015","article-title":"Surgical treatment of Aspergillus mycetomas of the maxillary sinus: review of the literature","volume":"103","author":"Costa","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2020110410412589300_CIW326C448","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00405-012-2121-5","article-title":"Sphenoid sinus fungus ball","volume":"270","author":"Karkas","year":"2013","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2020110410412589300_CIW326C449","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/bjophthalmol-2013-303763","article-title":"Orbital aspergillosis in immunocompetent patients","volume":"98","author":"Mody","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"2020110410412589300_CIW326C450","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1471-2334-11-250","article-title":"Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan","volume":"11","author":"Chen","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C451","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3109\/13693786.2010.498449","article-title":"Aspergillus endocarditis 2003\u20132009","volume":"49","author":"McCormack","year":"2011","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C452","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinf.2013.01.003","article-title":"Aspergillus endocarditis in the era of new antifungals: major role for antigen detection","volume":"67","author":"Riviere","year":"2013","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C453","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1086\/317550","article-title":"Fungal endocarditis: evidence in the world literature, 1965\u20131995","volume":"32","author":"Ellis","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C454","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00005792-200007000-00007","article-title":"Aspergillus valve endocarditis in patients without prior cardiac surgery","volume":"79","author":"Gumbo","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C455","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/432580","article-title":"Successful treatment of Aspergillus prosthetic valve endocarditis with oral voriconazole","volume":"41","author":"Reis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C456","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.41.1.13","article-title":"Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs","volume":"41","author":"Martin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C457","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1097-0142(19820101)49:1<48::AID-CNCR2820490112>3.0.CO;2-A","article-title":"Aspergillus pericarditis: clinical and pathologic features in the immunocompromised patient","volume":"49","author":"Walsh","year":"1982","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C458","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/516326","article-title":"Aspergillus pericarditis with tamponade: report of a successfully treated case and review","volume":"26","author":"Le Moing","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C459","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S1053-2498(02)00426-6","article-title":"Late Aspergillus fumigatus endomyocarditis with brain abscess as a lethal complication after heart transplantation","volume":"21","author":"Rueter","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"2020110410412589300_CIW326C460","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciq039","article-title":"Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy","volume":"52","author":"Studemeister","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C461","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jinf.2013.12.008","article-title":"Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome","volume":"68","author":"Gamaletsou","year":"2014","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C462","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1086\/514774","article-title":"Spinal Aspergillus osteomyelitis","volume":"28","author":"Vinas","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C463","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1086\/428734","article-title":"Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases","volume":"40","author":"Mouas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C464","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10096-003-0909-3","article-title":"Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review","volume":"22","author":"Stratov","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C465","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13693780802545600","article-title":"Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery","volume":"47","author":"Hodiamont","year":"2009","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C466","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1469-0691.2006.01471.x","article-title":"Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review","volume":"12","author":"Kumashi","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C467","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jinf.2005.08.016","article-title":"Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature","volume":"52","author":"Kirby","year":"2006","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C468","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/myc.12165","article-title":"Aspergillosis of bones and joints\u2014a review from 2002 until today","volume":"57","author":"Koehler","year":"2014","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C469","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0022-3476(86)81051-4","article-title":"Outbreak of primary cutaneous aspergillosis related to intravenous arm boards","volume":"108","author":"McCarty","year":"1986","journal-title":"J Pediatr"},{"key":"2020110410412589300_CIW326C470","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0195-6701(97)90199-7","article-title":"Fatal primary cutaneous aspergillosis in a bone marrow transplant recipient: nosocomial acquisition in a laminar-air flow room","volume":"36","author":"Bretagne","year":"1997","journal-title":"J Hosp Infect"},{"key":"2020110410412589300_CIW326C471","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/514718","article-title":"Primary cutaneous aspergillosis\u2014an emerging infection among immunocompromised patients","volume":"27","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C472","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14787210.2014.960849","article-title":"Fungal infections of the skin and nail: new treatment options","volume":"12","author":"Eldridge","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020110410412589300_CIW326C473","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0732-8893(02)00554-0","article-title":"Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature","volume":"46","author":"Nannini","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C474","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.0933-7407.2003.00922.x","article-title":"Fungal peritonitis in 15 patients on continuous ambulatory peritoneal dialysis (CAPD)","volume":"46","author":"Manzano-Gayosso","year":"2003","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C475","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3747\/pdi.2012.00042","article-title":"Diagnosis of Aspergillus niger peritonitis in a peritoneal dialysis patient by peritoneal galactomannan and beta-D-glucan detection","volume":"33","author":"Ates","year":"2013","journal-title":"Perit Dial Int"},{"key":"2020110410412589300_CIW326C476","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3747\/pdi.2012.00230","article-title":"Culture-negative Aspergillus peritonitis diagnosed by peritoneal biopsy","volume":"33","author":"Indramohan","year":"2013","journal-title":"Perit Dial Int"},{"issue":"suppl 2","key":"2020110410412589300_CIW326C477","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1177\/089686080902902S31","article-title":"Update on fungal peritonitis and its treatment","volume":"29","author":"Matuszkiewicz-Rowinska","year":"2009","journal-title":"Perit Dial Int"},{"key":"2020110410412589300_CIW326C478","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jac\/dkm074","article-title":"Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis","volume":"59","author":"van der Voort","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C479","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/jac\/dkn306","article-title":"Levels of amphotericin B lipid formulations in ascites","volume":"62","author":"Weiler","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C480","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/j.ajkd.2004.09.017","article-title":"Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients","volume":"45","author":"Peng","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2020110410412589300_CIW326C481","first-page":"212","article-title":"Peritonitis due to Aspergillus nidulans and its effective treatment with voriconazole: the first case report","volume":"31","author":"Ulusoy","year":"2011","journal-title":"Perit Dial Int"},{"key":"2020110410412589300_CIW326C482","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3747\/pdi.2010.00049","article-title":"Peritoneal dialysis-related infections recommendations: 2010 update","volume":"30","author":"Li","year":"2010","journal-title":"Perit Dial Int"},{"key":"2020110410412589300_CIW326C483","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00005792-197003000-00002","article-title":"Aspergillosis. The spectrum of the disease in 98 patients","volume":"49","author":"Young","year":"1970","journal-title":"Medicine (Baltimore)"},{"key":"2020110410412589300_CIW326C484","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0002-9343(73)90077-6","article-title":"Aspergillosis complicating neoplastic disease","volume":"54","author":"Meyer","year":"1973","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C485","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-006-5660-0","article-title":"Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature","volume":"34","author":"Eggimann","year":"2006","journal-title":"Infection"},{"key":"2020110410412589300_CIW326C486","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1469-0691.2010.03310.x","article-title":"A retrospective series of gut aspergillosis in haematology patients","volume":"17","author":"Kazan","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C487","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-006-0129-x","article-title":"Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder","volume":"85","author":"van der Velden","year":"2006","journal-title":"Ann Hematol"},{"key":"2020110410412589300_CIW326C488","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/jpsu.2002.32914","article-title":"Aspergillus cholangitis: a late complication after Kasai portoenterostomy","volume":"37","author":"Erdman","year":"2002","journal-title":"J Pediatr Surg"},{"key":"2020110410412589300_CIW326C489","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0090-4295(02)01746-6","article-title":"Primary bilateral parenchymal renal Aspergillus infection","volume":"60","author":"Lisson","year":"2002","journal-title":"Urology"},{"key":"2020110410412589300_CIW326C490","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/clinids\/21.1.210","article-title":"Renal aspergilloma due to Aspergillus flavus","volume":"21","author":"Khan","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C491","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/tid.12221","article-title":"Microwave ablation of a large renal aspergilloma","volume":"16","author":"Waller","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C492","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.idc.2013.09.004","article-title":"Diagnosis and management of fungal urinary tract infection","volume":"28","author":"Kauffman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"2020110410412589300_CIW326C493","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1099\/jmm.0.012799-0","article-title":"Management of obstructive renal failure caused by bilateral renal aspergilloma in an immunocompetent newborn","volume":"59","author":"Martinez-Pajares","year":"2010","journal-title":"J Med Microbiol"},{"key":"2020110410412589300_CIW326C494","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.otohns.2006.07.008","article-title":"Otomycosis: clinical features and treatment implications","volume":"135","author":"Ho","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2020110410412589300_CIW326C495","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ijporl.2007.12.005","article-title":"Ototopical antifungals and otomycosis: a review","volume":"72","author":"Munguia","year":"2008","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2020110410412589300_CIW326C496","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1017\/S0022215113000315","article-title":"Aspergillus petrous apicitis associated with cerebral and peritubular abscesses in an immunocompetent man","volume":"127","author":"Bhatt","year":"2013","journal-title":"J Laryngol Otol"},{"key":"2020110410412589300_CIW326C497","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/clinids\/19.5.866","article-title":"Invasive otitis externa due to Aspergillus species: case report and review","volume":"19","author":"Gordon","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C498","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/AAC.01220-08","article-title":"Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review","volume":"53","author":"Parize","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C499","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ceo.12055","article-title":"Neuro-ophthalmology of invasive fungal sinusitis: 14 consecutive patients and a review of the literature","volume":"41","author":"Thurtell","year":"2013","journal-title":"Clin Experiment Ophthalmol"},{"key":"2020110410412589300_CIW326C500","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clindermatol.2009.12.003","article-title":"Otomycosis: diagnosis and treatment","volume":"28","author":"Vennewald","year":"2010","journal-title":"Clin Dermatol"},{"key":"2020110410412589300_CIW326C501","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bjophthalmol-2012-301825","article-title":"Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial","volume":"96","author":"Prajna","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2020110410412589300_CIW326C502","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2020110410412589300_CIW326C503","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1442-9071.2010.02473.x","article-title":"Voriconazole versus natamycin as primary treatment in fungal corneal ulcers","volume":"39","author":"Arora","year":"2011","journal-title":"Clin Experiment Ophthalmol"},{"key":"2020110410412589300_CIW326C504","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2011.11.034","article-title":"Voriconazole for fungal corneal ulcers","volume":"119","author":"Parchand","year":"2012","journal-title":"Ophthalmology"},{"key":"2020110410412589300_CIW326C505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1469-0691.12126","article-title":"Mycotic keratitis: epidemiology, diagnosis and management","volume":"19","author":"Thomas","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C506","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ophtha.2009.10.004","article-title":"Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation","volume":"117","author":"Shi","year":"2010","journal-title":"Ophthalmology"},{"key":"2020110410412589300_CIW326C507","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000094708","article-title":"Endobronchial fungal disease: an under-recognized entity","volume":"74","author":"Karnak","year":"2007","journal-title":"Respiration"},{"key":"2020110410412589300_CIW326C508","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2012.06816.x","article-title":"Aspergillus bronchitis without significant immunocompromise","volume":"1272","author":"Chrdle","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"2020110410412589300_CIW326C509","doi-asserted-by":"crossref","first-page":"e98502","DOI":"10.1371\/journal.pone.0098502","article-title":"Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis","volume":"9","author":"Armstead","year":"2014","journal-title":"PLoS One"},{"key":"2020110410412589300_CIW326C510","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1378\/chest.130.1.222","article-title":"Aspergillus bronchitis in cystic fibrosis","volume":"130","author":"Shoseyov","year":"2006","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C511","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"Wald","year":"1997","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C512","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbmt.2004.02.006","article-title":"Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center","volume":"10","author":"Fukuda","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020110410412589300_CIW326C513","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C514","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2009.012633","article-title":"Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia","volume":"95","author":"Chabrol","year":"2010","journal-title":"Haematologica"},{"key":"2020110410412589300_CIW326C515","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2011.111","article-title":"Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT","volume":"47","author":"Molina","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C516","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1078155214539825","article-title":"Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Peksa","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"2020110410412589300_CIW326C517","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/422723","article-title":"Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis","volume":"39","author":"Siwek","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C518","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1399-3062.2007.00203.x","article-title":"Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient","volume":"9","author":"Tong","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C519","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C520","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/jac\/dkr271","article-title":"A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study)","volume":"66","author":"Cattaneo","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020110410412589300_CIW326C521","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1592\/phco.27.12.1644","article-title":"Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients","volume":"27","author":"Chou","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2020110410412589300_CIW326C522","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bmt.1705720","article-title":"Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and\/or systemic fungal infection","volume":"40","author":"de Fabritiis","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C523","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C524","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"key":"2020110410412589300_CIW326C525","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"key":"2020110410412589300_CIW326C526","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B","volume":"44","author":"Harousseau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410412589300_CIW326C527","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1086\/313654","article-title":"A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients","volume":"30","author":"Nucci","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C528","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann Intern Med"},{"key":"2020110410412589300_CIW326C529","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"2020110410412589300_CIW326C530","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2005.05727.x","article-title":"Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials","volume":"131","author":"Vardakas","year":"2005","journal-title":"Br J Haematol"},{"key":"2020110410412589300_CIW326C531","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"2020110410412589300_CIW326C532","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0002-9343(91)90184-Y","article-title":"Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation","volume":"91","author":"Rousey","year":"1991","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C533","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01716080","article-title":"Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: a single center experience from 1980 to 1995","volume":"24","author":"De Laurenzi","year":"1996","journal-title":"Infection"},{"key":"2020110410412589300_CIW326C534","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/165.5.891","article-title":"Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients","volume":"165","author":"Perfect","year":"1992","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C535","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bmt.2009.210","article-title":"Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD","volume":"45","author":"Gergis","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C536","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2009.08.015","article-title":"Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Amigues","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020110410412589300_CIW326C537","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.bmt.1704614","article-title":"A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation","volume":"34","author":"Grigg","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C538","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2014a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C539","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/QCO.0b013e3283630e67","article-title":"Is universal antifungal prophylaxis mandatory in lung transplant patients?","volume":"26","author":"Schaenman","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2020110410412589300_CIW326C540","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C541","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.healun.2005.05.003","article-title":"Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction","volume":"24","author":"Shitrit","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"2020110410412589300_CIW326C542","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1600-6143.2009.02734.x","article-title":"Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness","volume":"9","author":"Cadena","year":"2009","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C543","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11908-013-0380-y","article-title":"Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis","volume":"15","author":"Bhaskaran","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"2020110410412589300_CIW326C544","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00007890-200108150-00036","article-title":"Safety of aerosolized amphotericin B lipid complex in lung transplant recipients","volume":"72","author":"Palmer","year":"2001","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study","volume":"9","author":"Lowry","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C546","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.healun.2012.11.013","article-title":"Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant","volume":"32","author":"Monforte","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"2020110410412589300_CIW326C547","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0030-1249118","article-title":"Fungi and molds following lung transplantation","volume":"31","author":"Hosseini-Moghaddam","year":"2010","journal-title":"Semin Respir Crit Care Med"},{"key":"2020110410412589300_CIW326C548","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1378\/chest.123.3.800","article-title":"Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients","volume":"123","author":"Helmi","year":"2003","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C549","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1378\/chest.114.5.1321","article-title":"Pulmonary aspergillosis in cystic fibrosis lung transplant recipients","volume":"114","author":"Nunley","year":"1998","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C550","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/TP.0b013e3181c3c417","article-title":"Impact of mold infections in explanted lungs on outcomes of lung transplantation","volume":"89","author":"Vadnerkar","year":"2010","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C551","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1053-2498(02)00477-1","article-title":"Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management","volume":"22","author":"Singh","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"2020110410412589300_CIW326C552","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C553","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00005792-199903000-00003","article-title":"Invasive aspergillosis in transplant recipients","volume":"78","author":"Paterson","year":"1999","journal-title":"Medicine"},{"key":"2020110410412589300_CIW326C554","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1086\/430602","article-title":"Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study","volume":"41","author":"Gavalda","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C555","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/00007890-199709150-00009","article-title":"Invasive aspergillosis in liver transplant recipients in the 1990s","volume":"64","author":"Singh","year":"1997","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C556","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00007890-199602270-00029","article-title":"Incidence and significance of Aspergillus cultures following liver and kidney transplantation","volume":"61","author":"Brown","year":"1996","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C557","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2020110410412589300_CIW326C558","first-page":"399","article-title":"Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole","volume":"9","author":"Hayes","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"2020110410412589300_CIW326C559","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2004.00390.x","article-title":"Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis","volume":"4","author":"Munoz","year":"2004","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C560","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000189282","article-title":"Study of kidney rejection following simultaneous kidney-pancreas transplantation","volume":"74","author":"Cofan","year":"1996","journal-title":"Nephron"},{"key":"2020110410412589300_CIW326C561","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/00000658-198311000-00011","article-title":"Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management","volume":"198","author":"Weiland","year":"1983","journal-title":"Ann Surg"},{"key":"2020110410412589300_CIW326C562","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMcpc0801192","article-title":"Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation","volume":"358","author":"Fishman","year":"2008","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C563","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/infdis\/170.3.644","article-title":"Risk factors for invasive fungal infections complicating orthotopic liver transplantation","volume":"170","author":"Collins","year":"1994","journal-title":"J Infect Dis"},{"key":"2020110410412589300_CIW326C564","first-page":"38","article-title":"Fungal infections complicating orthotopic liver transplantation","volume":"106","author":"Karchmer","year":"1995","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"2020110410412589300_CIW326C565","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9343(97)80021-6","article-title":"The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland","volume":"103","author":"George","year":"1997","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C566","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF02114892","article-title":"Risk factors for systemic fungal infections in liver transplant recipients","volume":"14","author":"Briegel","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C567","first-page":"CD004291","article-title":"Antifungal agents for preventing fungal infections in solid organ transplant recipients","author":"Playford","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410412589300_CIW326C568","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10096-006-0182-3","article-title":"Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients","volume":"25","author":"Playford","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C569","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/TP.0000000000000393","article-title":"High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial","volume":"99","author":"Giannella","year":"2015","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C570","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/TP.0b013e31829d674f","article-title":"Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients","volume":"96","author":"Sun","year":"2013","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C571","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1086\/503844","article-title":"Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies","volume":"42","author":"Sipsas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C572","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C573","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/myc.12023","article-title":"Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive Aspergillus disease, a retrospective analysis","volume":"56","author":"Heinz","year":"2013","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C574","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJM200212263472618","article-title":"Multidrug resistance in Aspergillus fumigatus","volume":"347","author":"Warris","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C575","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2012.05.001","article-title":"Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis?","volume":"65","author":"Georgiadou","year":"2012","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C576","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/tid.12211","article-title":"Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis","volume":"16","author":"Fisher","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C577","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C578","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C579","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group","volume":"86","year":"1989","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C580","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C581","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"key":"2020110410412589300_CIW326C582","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C583","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C584","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children","volume":"158","author":"Caselli","year":"2012","journal-title":"Br J Haematol"},{"key":"2020110410412589300_CIW326C585","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10096-012-1794-4","article-title":"Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"32","author":"Maschmeyer","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C586","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/myc.12108","article-title":"Empirical amphotericin B therapy on day 4 or day 8 of febrile neutropenia","volume":"57","author":"Malhotra","year":"2014","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C587","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2008.355","article-title":"A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT","volume":"43","author":"Hebart","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C588","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/bmt.2010.38","article-title":"Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT","volume":"45","author":"Blennow","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C589","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C590","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/j.ijid.2011.01.011","article-title":"Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study","volume":"15","author":"Tan","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2020110410412589300_CIW326C591","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1128\/JCM.05316-11","article-title":"Evaluation of Aspergillus PCR protocols for testing serum specimens","volume":"49","author":"White","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020110410412589300_CIW326C592","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bmt.2011.58","article-title":"Standardization of Aspergillus PCR diagnosis","volume":"47","author":"Loeffler","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2020110410412589300_CIW326C593","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing","volume":"61","author":"White","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C594","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C595","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1378\/chest.112.5.1160","article-title":"Aspergillus airway colonization and invasive disease after lung transplantation","volume":"112","author":"Cahill","year":"1997","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C596","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: incidence and prognosis","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C597","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/ajt.12131","article-title":"Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: a two-center validation study","volume":"13","author":"Weigt","year":"2013","journal-title":"Am J Transplant"},{"key":"2020110410412589300_CIW326C598","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/tid.12071","article-title":"Preemptive treatment with voriconazole in lung transplant recipients","volume":"15","author":"Neoh","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2020110410412589300_CIW326C599","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00007890-199603270-00013","article-title":"Aspergillus infection in single and double lung transplant recipients","volume":"61","author":"Westney","year":"1996","journal-title":"Transplantation"},{"key":"2020110410412589300_CIW326C600","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1097\/TP.0000000000000743","article-title":"The effectiveness of culture-directed preemptive anti-Aspergillus treatment in lung transplant recipients at one year after transplant","volume":"99","author":"Hosseini-Moghaddam","year":"2015","journal-title":"Transplantation"},{"issue":"suppl 3","key":"2020110410412589300_CIW326C601","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C602","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s10096-012-1690-y","article-title":"Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial","volume":"31","author":"Cadranel","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C603","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1183\/09031936.00054810","article-title":"Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma","volume":"37","author":"Smith","year":"2011","journal-title":"Eur Respir J"},{"key":"2020110410412589300_CIW326C604","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"issue":"suppl 1","key":"2020110410412589300_CIW326C605","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1080\/13693780400025179","article-title":"The invasive and saprophytic syndromes due to Aspergillus spp","volume":"43","author":"Hope","year":"2005","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C606","doi-asserted-by":"crossref","first-page":"O480","DOI":"10.1111\/1469-0691.12473","article-title":"A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis","volume":"20","author":"Smith","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C607","doi-asserted-by":"crossref","first-page":"O960","DOI":"10.1111\/1469-0691.12643","article-title":"Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT","volume":"20","author":"Smith","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C608","doi-asserted-by":"crossref","first-page":"E197","DOI":"10.1111\/1469-0691.12133","article-title":"Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis","volume":"19","author":"Baxter","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2020110410412589300_CIW326C609","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myv020","article-title":"Antibody testing in aspergillosis\u2014quo vadis?","volume":"53","author":"Page","year":"2015","journal-title":"Med Mycol"},{"key":"2020110410412589300_CIW326C610","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1148\/radiology.165.1.3628758","article-title":"Intrathoracic aspergilloma: role of CT in diagnosis and treatment","volume":"165","author":"Roberts","year":"1987","journal-title":"Radiology"},{"key":"2020110410412589300_CIW326C611","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C612","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1378\/chest.06-2441","article-title":"Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients","volume":"131","author":"Camuset","year":"2007","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C613","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jinf.2005.08.022","article-title":"The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis","volume":"52","author":"Jain","year":"2006","journal-title":"J Infect"},{"key":"2020110410412589300_CIW326C614","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.12-0014","article-title":"Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis","volume":"144","author":"Al-shair","year":"2013","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C615","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"Felton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410412589300_CIW326C616","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jiac.2014.02.003","article-title":"Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles","volume":"20","author":"Koyama","year":"2014","journal-title":"J Infect Chemother"},{"key":"2020110410412589300_CIW326C617","first-page":"CD008711","article-title":"Antifibrinolytic therapy to reduce haemoptysis from any cause","volume":"4","author":"Prutsky","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410412589300_CIW326C618","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/icvts\/ivt383","article-title":"Does tranexamic acid stop haemoptysis?","volume":"17","author":"Moen","year":"2013","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2020110410412589300_CIW326C619","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1148\/radiology.168.2.3393655","article-title":"Control of hemoptysis: systemic angiography and anastomoses of the internal mammary artery","volume":"168","author":"Jardin","year":"1988","journal-title":"Radiology"},{"key":"2020110410412589300_CIW326C620","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1378\/chest.121.3.789","article-title":"Bronchial artery embolization: experience with 54 patients","volume":"121","author":"Swanson","year":"2002","journal-title":"Chest"},{"key":"2020110410412589300_CIW326C621","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00270-005-0329-0","article-title":"Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization","volume":"29","author":"Corr","year":"2006","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2020110410412589300_CIW326C622","first-page":"319","article-title":"Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes","volume":"27","author":"Serasli","year":"2008","journal-title":"Int Angiol"},{"key":"2020110410412589300_CIW326C623","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410412589300_CIW326C624","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/j.ijid.2009.07.011","article-title":"Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases","volume":"14","author":"Nam","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2020110410412589300_CIW326C625","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/thoraxjnl-2013-203988","article-title":"Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis","volume":"69","author":"Keir","year":"2014","journal-title":"Thorax"},{"key":"2020110410412589300_CIW326C626","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1510\/icvts.2011.265553","article-title":"Surgery for aspergilloma: time trend towards improved results?","volume":"13","author":"Lejay","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2020110410412589300_CIW326C627","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/icvts\/ivs130","article-title":"Surgical treatment for pulmonary aspergilloma: a 35-year experience in the Chinese population","volume":"15","author":"Chen","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2020110410412589300_CIW326C628","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jtcvs.2009.01.019","article-title":"Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment","volume":"138","author":"Lee","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2020110410412589300_CIW326C629","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/021849230601400512","article-title":"Analysis of surgical treatment for pulmonary aspergilloma","volume":"14","author":"Demir","year":"2006","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"2020110410412589300_CIW326C630","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2013.10.050","article-title":"Surgical therapy of pulmonary aspergillomas: a 30-year North American experience","volume":"97","author":"Muniappan","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"2020110410412589300_CIW326C631","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.athoracsur.2013.08.010","article-title":"Video-assisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure","volume":"97","author":"Chen","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"2020110410412589300_CIW326C632","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1510\/icvts.2009.232066","article-title":"Video-assisted thoracic surgery for pulmonary aspergilloma","volume":"10","author":"Ichinose","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2020110410412589300_CIW326C633","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1749-8090-8-180","article-title":"Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence\u2014a National Centre's experience","volume":"8","author":"Farid","year":"2013","journal-title":"J Cardiothorac Surg"},{"key":"2020110410412589300_CIW326C634","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ejcts\/ezt336","article-title":"A retrospective review comparing the treatment outcomes of emergency lung resection for massive haemoptysis with and without preoperative bronchial artery embolization","volume":"45","author":"Alexander","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"2020110410412589300_CIW326C635","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1749-6632.2012.06827.x","article-title":"Multifocal pulmonary aspergillomas: case series and review","volume":"1272","author":"Pendleton","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"2020110410412589300_CIW326C636","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2011.12.970","article-title":"Fungi and allergic lower respiratory tract diseases","volume":"129","author":"Knutsen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2020110410412589300_CIW326C637","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"2020110410412589300_CIW326C638","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/myc.12214","article-title":"Cut-off values of serum IgE (total and A. fumigatus-specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma","volume":"57","author":"Agarwal","year":"2014","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C639","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1183\/09031936.00139513","article-title":"Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis","volume":"43","author":"Moss","year":"2014","journal-title":"Eur Respir J"},{"key":"2020110410412589300_CIW326C640","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1439-0507.2008.01680.x","article-title":"Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in north India","volume":"53","author":"Agarwal","year":"2010","journal-title":"Mycoses"},{"key":"2020110410412589300_CIW326C641","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-7022-4-14","article-title":"Fungal allergy in asthma\u2014state of the art and research needs","volume":"4","author":"Denning","year":"2014","journal-title":"Clin Transl Allergy"},{"key":"2020110410412589300_CIW326C642","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ppul.22937","article-title":"Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence","volume":"49","author":"Tanou","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"2020110410412589300_CIW326C643","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rmed.2004.05.006","article-title":"Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis","volume":"99","author":"Kellett","year":"2005","journal-title":"Respir Med"},{"key":"2020110410412589300_CIW326C644","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/cea.12333","article-title":"Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review","volume":"44","author":"Moreira","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"2020110410412589300_CIW326C645","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N Engl J Med"},{"key":"2020110410412589300_CIW326C646","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/02770903.2014.958853","article-title":"Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)","author":"Chishimba","year":"2015","journal-title":"J Asthma"},{"key":"2020110410412589300_CIW326C647","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11882-012-0320-1","article-title":"Fungal disease of the nose and sinuses: an updated overview","volume":"13","author":"Chang","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"2020110410412589300_CIW326C648","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaci.2011.11.039","article-title":"Fungal disease of the nose and paranasal sinuses","volume":"129","author":"Thompson","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"2020110410412589300_CIW326C649","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjmed.2010.12.005","article-title":"Complications of allergic fungal sinusitis","volume":"124","author":"Bozeman","year":"2011","journal-title":"Am J Med"},{"key":"2020110410412589300_CIW326C650","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11882-012-0329-5","article-title":"Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis","volume":"13","author":"Howard","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"2020110410412589300_CIW326C651","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/alr.21352","article-title":"Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence-based review and recommendations","volume":"4","author":"Gan","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"2020110410412589300_CIW326C652","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020110410412589300_CIW326C653","first-page":"870","article-title":"Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis","volume":"37","author":"Chan","year":"2008","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"2020110410412589300_CIW326C654","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2500\/ajra.2009.23.3315","article-title":"The role of itraconazole in recalcitrant fungal sinusitis","volume":"23","author":"Seiberling","year":"2009","journal-title":"Am J Rhinol Allergy"},{"key":"2020110410412589300_CIW326C655","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/alr.20088","article-title":"Oral antifungal therapy for chronic rhinosinusitis and its subtypes: a systematic review","volume":"1","author":"Thanasumpun","year":"2011","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/4\/e1\/34129734\/ciw326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/4\/e1\/34129734\/ciw326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T21:20:39Z","timestamp":1718659239000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/63\/4\/e1\/2595039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":655,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,6,29]]},"published-print":{"date-parts":[[2016,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw326","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,8,15]]},"published":{"date-parts":[[2016,6,29]]}}}